• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form F-3/A filed by Trinity Biotech plc

    11/29/24 4:45:36 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TRIB alert in real time by email
    F-3/A 1 zk2432381.htm F-3/A

    Registration No. 333-283273

    As filed with the Securities and Exchange Commission on November 29, 2024

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
     
    Washington, D.C. 20549



    Amendment No. 1
    to
    FORM F-3
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933



    TRINITY BIOTECH PLC
     (Exact name of registrant as specified in its charter)

    Republic of Ireland
    (State or other jurisdiction of
    incorporation or organization)
    Not Applicable
    (I.R.S. Employer
    Identification No.)

    IDA Business Park
    Bray, County Wicklow
    A98 H5C8
    Ireland
    +353 1 276 9800
    (Address and telephone number of registrant's principal executive offices)
     
    Puglisi & Associates
    850 Library Avenue, Suite 204
    Newark, Delaware 19711
    Tel. (302) 738-6680
     (Name, address and telephone number of agent for service)
                                                                                                   

    Copies of all communications, including communications sent to agent for service, should be sent to:

    Steven J. Glusband, Esq.
    Mary Brown, Esq.
    Carter Ledyard & Milburn LLP
    28 Liberty Street
    New York, New York 10005
    (212) 732-3200
     
    David Fitzgibbon, Esq.
    David Jones, Esq.
    Matheson LLP
    70 Sir John Rogerson's Quay
    Dublin 2 Ireland
    +353 1 232 2000
                                                                                                   

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.
                                                                                                   

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box.  ☐



    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.  ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐

    If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

    Emerging growth company  ☐

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     † The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

                                                                                                   

    The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.


    EXPLANATORY NOTE

    The sole purpose of this Amendment No. 1 to the Registration Statement on Form F-3 (333-283273) (the “Registration Statement”) is to file Exhibit 4.3 (the “Exhibit”). Accordingly, this Amendment No. 1 consists only of the facing page, this explanatory note, Part II, including the signature page and exhibit index, and the Exhibit. This Amendment No. 1 does not contain a copy of the prospectus that was included in the Registration Statement and is not intended to amend or delete any part of the prospectus.



    PART II
    INFORMATION NOT REQUIRED IN PROSPECTUS
     
    Item 8. Indemnification of Directors and Officers.
     
    The registrant’s constitution provides that every director and other officer of the registrant (other than an auditor) shall be indemnified out of the assets of the registrant against any liability incurred by him in defending any proceedings, whether civil or criminal, in relation to his acts while acting in such office in which judgment is given in his favor or in which he is acquitted or in connection with any application in which relief is granted to him by the court under the Irish Companies Act 2014. We have entered into indemnification agreements with directors and senior management. Each such indemnification agreement provides the director or office holder with indemnification permitted under applicable law and to the extent that these liabilities are not covered by directors’ and officers’ insurance.
     
    Item 9.  Exhibits.
     
    The index to exhibits appears below on the page immediately following the signature pages of this Registration Statement.
     
    Item 10.  Undertakings.
     
    (a)           The undersigned registrant hereby undertakes:
     

    (1)
    to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
     

    (i)
    to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933 (the “Securities Act”);
     

    (ii)
    to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement.  Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the ‘‘Calculation of Registration Fee’’ table in the effective registration statement; and
     

    (iii)
    to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in this Registration Statement;
     
    provided, however, that paragraphs (i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) that are incorporated by reference in this Registration Statement or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement.
     

    (2)
    that, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     

    (3)
    to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
     




    (4)
    to file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act of 1933 need not be furnished, provided, that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities Act of 1933 or Rule 3-19 of Regulation S-X if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Form F-3.
     

    (5)
    that, for the purpose of determining any liability under the Securities Act to any purchaser:
     

    (i)
    each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be a part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and


    (ii)
    each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.
     

    (6)
    that, for the purpose of determining liability of a registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
     

    (i)
    any preliminary prospectus or prospectus of the undersigned registrant to the offering required to be filed pursuant to Rule 424;
     

    (ii)
    any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an undersigned registrant;
     

    (iii)
    the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
     

    (iv)
    any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
     
    II - 2


    (b)
    The registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (c)
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the provisions referred to in Item 8, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
     
    (d)
    The registrant hereby undertakes that, for purposes of determining any liability under the Securities Act,
     

    (1)
    the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective.
     

    (2)
    each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (e)
    The registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of section 310 of the Trust Indenture Act (“Act”) in accordance with the rules and regulations prescribed by the Commission under section 305(b)2 of the Act.
     
    II - 3


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act, the Registrant has duly caused this Amendment No. 1 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Wicklow, Ireland, on November 29, 2024.
     
     
    TRINITY BIOTECH PLC
     
     
     
     
    By:
    /s/ John Gillard
     
     
    John Gillard
     
     
    Chief Executive Officer

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below on November 29, 2024 by or on behalf of the following persons in the capacities indicated.

    Signature
     
    Title
     
     
     
    /s/ John Gillard
     
    Chief Executive Officer (Principal Executive Officer), Company Secretary and Director
    John Gillard
     
     
     
     
     
    *
     
    Chief Financial Officer
    Louise Tallon
     
     
     
     
     
    *
     
    Director
    James Walsh
     
     
     
     
     
     *
     
    Director
    Ronan O’Caoimh
     
     
     
     
     
     *
     
    Director
    Thomas Lindsay
     
     
     
     
     
    *
     
    Director
    Andrew Omidvar
     
     
     
     
     
    *By:
    /s/ John Gillard
     
    Name: 
    John Gillard
     
    Title:
    Attorney-in-fact
     

    II - 4


    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of the Registrant, has signed this Amendment No. 1 to the registration statement on November 29, 2024.

    Puglisi & Associates
     
     
     
     
    By:
    /s/ Donald J. Puglisi
     
     
    Name: Donald J. Puglisi
     
     
    Title:  Managing Director
     

    II - 5


    Exhibit No.
     
    Description of Exhibit
    4.1
    Constitution of Trinity Biotech plc included as Exhibit 1.1 to our Annual Report on Form 20-F (File No. 000-22320 as amended by Form 20-F/A filed with the Commission on May 25, 2022).
    4.2
    Form of Deposit Agreement dated as of October 21, 1992, as amended and restated, among Trinity Biotech plc, The Bank of New York as Depositary, and all Owners and holders from time to time of American Depositary Receipts issued thereunder (included as Exhibit 1 to our Form F-6 (File No. 333-111946), filed with the Commission on January 15, 2004).
    4.3
    Financial Advisory Agreement between Craig-Hallum Capital Group LLC and Trinity Biotech plc dated October 10, 2024
    5.1*
    Opinion of Matheson LLP
    23.1*
    Consent of Grant Thornton
    23.2*
    Consent of Matheson LLP (contained in Exhibit 5.1)
    24.1*
    Power of Attorney (included in the signature page to the Registration Statement)
    107*
    Calculation of Registration Fee
    ________________
    *Previously Filed.
    II - 6

    Get the next $TRIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TRIB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives

    -  Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 -  Equity settlement mechanisms also agreed for milestone payments and contingent acquisition consideration DUBLIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a series of agreements with funds managed by Perceptive Advisors designed to enhance the Company's financial flexibility and to optimize its capital structure in support of its ongoing and future growth projects. These transact

    12/23/25 8:50:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests

    - TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA1positive operations in Q3 2025 and expects to achieve strong additional profitability growth in Q1 and Q2 2026 through continued strong execution on its Comprehensive Transformation Plan DUBLIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received an order for 9 million units of its flagship HIV screening product, TrinScreen HIV. This significant order marks a pivotal momen

    12/23/25 7:32:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances

    Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech's competitive position in the $2B+ HbA1c market DUBLIN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has secured regulatory clearances in multiple countries,  enabling the expanded rollout of its next-generation high-capacity HbA1c column system for the Premier Hb9

    12/15/25 9:15:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TRIB
    SEC Filings

    View All

    SEC Form EFFECT filed by Trinity Biotech plc

    EFFECT - TRINITY BIOTECH PLC (0000888721) (Filer)

    1/26/26 12:15:30 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 424B3 filed by Trinity Biotech plc

    424B3 - TRINITY BIOTECH PLC (0000888721) (Filer)

    1/23/26 5:14:18 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form F-1 filed by Trinity Biotech plc

    F-1 - TRINITY BIOTECH PLC (0000888721) (Filer)

    1/15/26 4:27:31 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TRIB
    Leadership Updates

    Live Leadership Updates

    View All

    Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

    DUBLIN, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Paul Tivnan to its Board of Directors as a Non-Executive Director. Mr. Tivnan brings over 25 years of senior leadership experience in finance, capital markets, and corporate governance across the infrastructure, energy, shipping, and cleantech sectors. He currently serves as Chief Financial Officer of Deriva Energy LLC, one of the largest independent renewable power producers in the United States and a Brookfield portfolio company. His previous

    8/21/25 9:00:23 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

    DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring ("CGM") technology with the appointment of Barclays Capital Inc. ("Barclays") as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan. With substantial progress in developing its differentiated and

    3/13/25 7:30:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

    DUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) --  Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Adrian Donohue as Chief Commercial Officer. Mr. Donohue brings more than 25 years of experience in the sales and marketing of healthcare products. John Gillard, President and Chief Executive Officer of Trinity Biotech, said, "We are resolute in continuing to execute on our transformation agenda, which will drive greater performance and profitability in our existing product lines, including supporting continued growth in our newest r

    9/3/24 9:55:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TRIB
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Announces Agreements to Strengthen Capital Structure and Support Growth Initiatives

    -  Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 -  Equity settlement mechanisms also agreed for milestone payments and contingent acquisition consideration DUBLIN, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has entered into a series of agreements with funds managed by Perceptive Advisors designed to enhance the Company's financial flexibility and to optimize its capital structure in support of its ongoing and future growth projects. These transact

    12/23/25 8:50:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances

    Company advances its mission to deliver next-generation diabetes management solutions and expand global market penetration Next-generation column technology enhances efficiency, expands recurring revenue potential, and strengthens Trinity Biotech's competitive position in the $2B+ HbA1c market DUBLIN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has secured regulatory clearances in multiple countries,  enabling the expanded rollout of its next-generation high-capacity HbA1c column system for the Premier Hb9

    12/15/25 9:15:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Secures Major Regulatory Approval for Offshored and Outsourced Manufacturing of Its Market Leading Uni-Gold Rapid HIV Test, Further Accelerating Financial Performance Transformation

    DUBLIN, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has received World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing activities of its market leading Uni-Gold™ HIV rapid test, a well-established and cornerstone diagnostic product used in HIV screening programs internationally. This regulatory approval marks a further critical milestone in the Company's comprehensive transformation plan aimed at driving sustainable profitability. This major regulatory approval enables

    11/18/25 9:00:00 AM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TRIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    11/14/24 5:26:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D/A filed by Trinity Biotech plc (Amendment)

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    5/1/24 4:57:00 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13D filed by Trinity Biotech plc

    SC 13D - TRINITY BIOTECH PLC (0000888721) (Subject)

    2/9/24 7:51:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care